Genomic features of pneumococcal strains isolated from paediatric patients with invasive disease during pneumococcal conjugate vaccine introduction in Lima, Peru
Authors:
- Brayan E. GonzalesBGBrayan E. Gonzales
- David DurandDDDavid Durand
- Erik H. MercadoEMErik H. Mercado
- Marcela Lopez-BriceñoMLMarcela Lopez-Briceño
- Luis GonzálezLGLuis González
- Grupo Peruano de Investigación En Neumococo (Gpin)G(Grupo Peruano de Investigación En Neumococo (Gpin)
- Theresa J. OchoaTOTheresa J. Ochoa
Open Access
- 3 February 2026
- journal article
- research article
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (2)
Abstract
To determine changes in the pneumococcal serotypes, sequence types (STs), clonal complexes (CCs) and the frequency of antimicrobial resistance genes after the introduction of pneumococcal conjugate vaccines (PCVs) in Lima, Peru. Retrospective multicentre study analysing whole-genome sequencing (WGS) data from three passive surveillance studies of invasive pneumococcal disease (IPD) in paediatric patients in Lima (2006–2020). Pneumococcal typing and antimicrobial resistance were analysed using in silico genomic tools. CCs were identified with eBURST and phylogenetic results were visualized using PHYLOViZ. 262 pneumococcal isolates were analysed (104 from IPD1, 70 from IPD2 and 88 from IPD3), 55.3% from children under 2 years old, 53.1% from patients with pneumonia and 28.5% with meningitis. After the introduction of PCVs, vaccine serotypes decreased, while serotype 19A and non-vaccine serotypes increased. The predominant STs were ST156 in IPD1 ( n =25) and in IPD2 ( n =7); and ST320 ( n =38) and ST230 ( n =15) in IPD3. Sixteen CC were identified, the most frequent were CC1421 ( n =58) and CC156 ( n =36). The overall penicillin non-susceptibility (NS) increased from 21.8% in IPD1 to 28.6% in IPD3, ceftriaxone-NS increased from 10% to 13.1% and macrolide-NS from 24.8% to 85.7% respectively. Resistance markers for macrolides, tetracycline and cotrimoxazole increased post-PCV13. WGS predicted antimicrobial resistance with high concordance, though some discrepancies were noted with phenotypic testing methods. Important changes in the distribution of serotype and ST, especially among vaccine serotypes, have been observed. These findings highlight the importance of monitoring vaccine effectiveness and tracking changes in bacterial populations to guide future vaccine implementation.Keywords
Funding Information
- Pfizer (ID#76571479)
This publication has 33 references indexed in Scilit:
- Streptococcus pneumoniae serotype 19A in hospitalized children with invasive pneumococcal disease after the introduction of conjugated vaccines in Lima, PeruJournal of Infection and Public Health, 2023
- Highly Resistant Serotype 19A Streptococcus pneumoniae of the GPSC1/CC320 Clone from Invasive Infections in Poland Prior to Antipneumococcal Vaccination of ChildrenInfectious Diseases and Therapy, 2023
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failuresVaccine, 2021
- Invasive pneumococcal disease in Canada 2010–2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccinesVaccine, 2021
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Infectious Diseases, 2018
- Antimicrobial resistance determinants and susceptibility profiles of pneumococcal isolates recovered in Trinidad and TobagoJournal of Global Antimicrobial Resistance, 2017
- Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United StatesClinical Microbiology and Infection, 2016
- Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USAClinical Microbiology and Infection, 2016
- Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort studyThe Lancet Infectious Diseases, 2015